fbpx Skip to main content
fda

FDA Grants 501(k) Market Clearance to Vivos Therapeutics’ mmRNA Oral Appliance for Treating Mild to Moderate Sleep Apnea

READ MORE

An Important Breakthrough in the

Treatment for Mild-to-Moderate

Obstructive Sleep Apnea

Vivos Therapeutics Inc., is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA.

Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA.

financial review

Vivos Therapeutics Second Quarter 2021 Financial Results Conference Call

Replay from August 12, 2021  |  5:00pm (EST Time)
Listen Now

Email Alerts

Stay informed and receive company updates straight to your inbox

Sign Up Now
CASE STUDY

Real World Data with DNA Appliance using Maxillary Expansion to Treat Obstructive Sleep Apnea

thumb devices

VivoScore

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA), today announced the launch of VivoScore™, powered by SleepImage®.

Read Now

Latest Stock Information

Investor Presentation

Download the Vivos Investor Presentation.

Download Now
presentation

The Annual Meeting of Stockholders

July 28, 2021 at 12:46 p.m. (Mountain Time)
vivos handbook
Fourth Quarter and Full Year 2020 Financial Results
Read Now

Vivos Therapeutics Presentation at the H.C. Wainwright 23rd Annual Global Investment Conference

7:00 am EDT  |  Monday, September 13, 2021
Institutional or retail investors may also listen to the company presentation online HERE.

Vivos Therapeutics News + Events!

News + Events

Watch the Vivos Therapeutics Presentation at the Benzinga Healthcare Small Cap Conference

Corporate Leadership

Our leadership team is devoted to a singular mission - to rid the world of sleep apnea.

19,000

Patients Treated

1,250

Doctors Integrated + Trained

1

Over 1B Potential Patients

Investor Relations Contacts

Home Office

Vivos Therapeutics, Inc.
(866) 908-4867
9135 S Ridgeline Blvd
Suite 100
Highlands Ranch, CO
80129

Capital Markets

Edward Loew
Investment Relations Officer
(602) 903-0095
9137 S Ridgeline Blvd
Suite 135
Highlands Ranch, CO
80129

Investor Relations

Phil Carlson / Scott Eckstein
KCSA Strategic Communications
212-896-1210
[email protected]

Transfer Agent

Vstock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
Phone: 212.828.8436
Fax: 646-536-3179
Email: [email protected]